Abstracts tagged "Clinical Osteoporosis"

Abstract Number: 2112 • ACR Convergence 2024
Discontinuation and Non-Publication of Osteoporosis Studies: An Observational Analysis of 7,670,624 Patients
Mohamed Abdelsalam¹, Asmaa al-Najjar², omnia Samy³, Rawan morse⁴, roaa Rafat⁵ and Mona Sajed⁶, ¹Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, ²Faculty of medicine - Al-Azhar university in Gaza, Gaza, Palestinian Territories, ³Faculty of medicine - Zagazig university, Al Zagazig, Egypt, ⁴Medical Research Group of Egypt, Bur sa'id, Egypt, ⁵Faculty of medicine, Ahfad University for Women, Khartoum, Sudan, Cairo, Egypt, ⁶Faculty of Pharmacy - Al-Azhar university for girls, Mansoura, Ad Daqahliyah, Egypt
Background/Purpose: Osteoporosis (OP) is one of the most common diseases, especially in old age, and as the population ages, the burden of osteoporosis is expected…
Abstract Number: 2113 • ACR Convergence 2024
Discontinuation and Non-publication of Postmenopausal Osteoporosis Clinical Studies: A Cross-sectional Analysis of 345,435 Patients
Mohamed Abdelsalam¹, yasmeen Alabdallat², Yousef Hussein³, Mona Sajed⁴, Maryam Taha⁵, Rawan morse⁶, Wessam Selima⁷ and Ahmed Zabady⁸, ¹Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, ²Faculty of medicine - Hashemite university, Zarqa, Jordan, ³Faculty of medicine - Benha university, Benha, Egypt, ⁴Faculty of Pharmacy - Al-Azhar university for girls, Mansoura, Ad Daqahliyah, Egypt, ⁵Faculty of medicine - Ain Shams university, Madinat Nasr, Al Qahirah, Egypt, ⁶Medical Research Group of Egypt, Bur sa'id, Egypt, ⁷Anaesethia & pain management department, Faculty of medicine, Ain Shams University, Cairo, Egypt, ⁸Faculty of science - Damanhour university, Cairo, Egypt
Background/Purpose: Postmenopausal osteoporosis (PMOP) significantly contributes to global fracture rates annually, with its silent progression complicating early detection and intervention. Effective management strategies are crucial,…
Abstract Number: 2116 • ACR Convergence 2024
Artificial Intelligence Classifier for Osteoporosis Detection from Chest Radiographs: Performance Evaluation and Literature Comparison with Quantitative Ultrasound
Miso jang¹ and Minjun Kim², ¹Promedius, inc., Seoul Chuk Hospital, Seoul, Republic of Korea, ²Promedius, inc., Seoul, Republic of Korea
Background/Purpose: Osteoporosis is a common condition that often goes unnoticed until it results in fractures, significantly increasing morbidity and mortality rates. Recent advancements in deep…
Abstract Number: 2130 • ACR Convergence 2024
Post-fracture Survival for Rheumatoid Arthritis Patients Is Not Improving
Owen Taylor-Williams¹, Johannes Nossent² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Western Australia, Australia, ²University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ³SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Improved disease control for articular manifestations of Rheumatoid arthritis (RA), has resulted in more attention being directed to extra-articular (ExRA) manifestations (cardiovascular events, osteoporosis,…
Abstract Number: 2144 • ACR Convergence 2024
Impact of Immunogenicity on Clinical Outcomes in Postmenopausal Women with Osteoporosis: Results from a Randomized Controlled Phase 3 Study to Compare CT-P41 (Proposed Denosumab Biosimilar) and Reference Denosumab
Jean-Yves Reginster¹, Stuart L. Silverman², Edward Czerwinski³, Przemyslaw Borowy⁴, Tomasz Budlewski⁵, Joanna Kwiatek⁶, Svitlana Postol⁷, Airi Põder⁸, Jerzy Supronik⁹, SungHyun Kim¹⁰, JeeHye Suh¹⁰, GoEun Yang¹⁰, NooRi Han¹⁰, NaHyun Kim¹⁰ and SeoHee Bae¹⁰, ¹Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, ²OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, ³Krakowskie Centrum Medyczne, Kraków, Poland, ⁴Krakowskie Centrum Medyczne, Krakow, Poland, ⁵Department of Rheumatology, Medical University of Lodz, Lodz, Poland, ⁶Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, ⁷Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, ⁸Clinical Research Centre Ltd, Tartu, Estonia, ⁹Osteo-Medic s.c., Białystok, Poland, ¹⁰Celltrion, Inc., Incheon, Republic of Korea

Background/Purpose: CT-P41 has been developed as a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator…
Abstract Number: 2563 • ACR Convergence 2024
Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial
Jean-Yves Reginster¹, Stuart L. Silverman², Edward Czerwinski³, Przemyslaw Borowy⁴, Tomasz Budlewski⁵, Joanna Kwiatek⁶, Svitlana Postol⁷, Airi Põder⁸, Jerzy Supronik⁹, SungHyun Kim¹⁰, JeeHye Suh¹⁰, GoEun Yang¹⁰, NooRi Han¹⁰, NaHyun Kim¹⁰ and SeoHee Bae¹⁰, ¹Biochemistry Dept, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia, CLARENS, Switzerland, ²OMC clinical research center and Cedars Sinai Medical Center, Beverly Hills, CA, ³Krakow Medical Centre, Kraków, Poland, ⁴Krakowskie Centrum Medyczne, Krakow, Poland, ⁵Department of Rheumatology, Medical University of Lodz, Lodz, Poland, ⁶Centrum Medyczne Poznan - PRATIA, Skorzewo, Poland, ⁷Medical Center of Medbud - Clinic LLC, Kyiv, Ukraine, ⁸Clinical Research Centre Ltd, Tartu, Estonia, ⁹Osteo-Medic s.c., Białystok, Poland, ¹⁰Celltrion, Inc., Incheon, Republic of Korea
Background/Purpose: CT-P41 is a proposed biosimilar of the reference denosumab (DEN), a fully human monoclonal antibody that binds the cytokine receptor activator of NF-κb ligand…
Abstract Number: 2123 • ACR Convergence 2023
Dose Trabecular Bone Score (TBS) Add Predictive Value to Fracture Risk Assessment (FRAX) in Rheumatoid Arthritis?
Jia-Feng Chen¹, Tien-Tsai Cheng² and Hong-Yo Kang³, ¹Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, ²Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University, College of Medicine, Kaohsiung, Taiwan, ³Graduate Institute of Clinical Medical Sciences, Chang Gung University, College of Medicine, Kaohsiung, Taiwan
Background/Purpose: Trabecular bone score (TBS) of lumbar spine is a dual X-ray densitometry (DXA)-based tool to evaluate bone microarchitecture, providing information on bone quality in…
Abstract Number: 0998 • ACR Convergence 2023
Barriers and Facilitators for Osteoporosis and Sarcopenia Care for Persons Living with HIV in Peru: HIV Physician and Coordinator Perspectives
Rebecca Slotkin¹, Daniel Granda Calderón², Joselito Malca Hernandez², Diego Cabrera³, Carlos Manuel Benites Villafane⁴, Patricia Jannet García⁵ and Evelyn Hsieh⁶, ¹Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health, New Haven, CT, ²Facultad de Medicina Alberto Hurtado de la Universidad Peruana Cayetano Heredia, Lima, Peru, ³Yale University, Department of Medicine, Section of Rheumatology; Department of Internal Medicine, Waterbury Hospital, New Haven, CT, ⁴Ministerio de Salud, Peru, Lima, Peru, ⁵Epidemiology, STD, and HIV Unit, School of Public Health, Universidad Peruana Cayetano Heredia, Lima, Peru, ⁶Yale University, Department of Medicine, Section of Rheumatology; Yale School of Public Health; Section of Rheumatology, VA Connecticut Healthcare System, Westport, CT
Background/Purpose: Persons living with HIV (PLWH) have a higher risk of developing age-related non-communicable diseases (NCDs), such as osteoporosis and sarcopenia. In Peru, HIV providers…
Abstract Number: 1997 • ACR Convergence 2023
A Randomized, Double-blind, Phase III Study to Compare SB16 (Proposed Denosumab Biosimilar) to Reference Denosumab in Patients with Postmenopausal Osteoporosis
Richard Eastell¹, Bente Langdahl², Yoon-Sok Chung³, Rafal Plebanski⁴, Edward Czerwinski⁵, Eva Dokoupilova⁶, Jerzy Supronik⁷, Jan Rosa⁸, Anna Rowińska-Osuch⁹, Ki-Hyun Baek¹⁰, Audrone Urboniene¹¹, Sohui Ahn¹², Younghee Rho¹² and Jisuk Ban¹², ¹University of Sheffield, Sheffield, United Kingdom, ²Aarhus University Hospital, Aarhus, Denmark, ³Ajou University Hospital, Suwon, South Korea, ⁴Klinika Zdrowej Kosci, Łódź, Poland, ⁵Futuremeds, Krakowskie Centrum Medyczne sp z oo, Krakow, Poland, ⁶Masaryk University, Faculty of Pharmacy, Department of Pharmaceutical Technology; MEDICAL PLUS sro, Brno, Czech Republic, ⁷OsteoMedic sc A Racewicz J Supronik, Bialystok, Poland, ⁸Affidea Praha, s.r.o.; Faculty of Medicine in Hradec Kralove, Charles University, Prague; Hradec Kralove, Czech Republic, ⁹ETG Warszawa, Warszawa, Poland, ¹⁰Yeouido ST. Mary's Hospital, Seoul, South Korea, ¹¹JSC Saules seimos medicinos centras, Kaunas, Lithuania, ¹²Samsung Bioepis, Incheon, South Korea
Background/Purpose: SB16 is a human monoclonal antibody to the receptor activator of nuclear factor κΒ ligand that has been developed as a proposed biosimilar to…
Abstract Number: 0070 • ACR Convergence 2022
Post-operative Delirium and Cognitive Impairment: An Analysis of Predictors and 120-day Outcomes in England Using the National Hip Fracture Database (NHFD)
Samuel Hawley¹, Dominic Inman², Celia Gregson¹, Michael Whitehouse¹, Antony Johansen³ and Andrew Judge¹, ¹University of Bristol, Bristol, United Kingdom, ²Northumbria Healthcare NHS Foundation Trust, Northumbria, United Kingdom, ³Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Post-operative delirium and cognitive impairment are common after hip fracture. We set out to identify risk factors and examine the association with returning home…
Abstract Number: 1314 • ACR Convergence 2022
Response Rates for Lumbar Spine, Total Hip, and Femoral Neck Bone Mineral Density with Abaloparatide in Men: Results from the ATOM Study
Ruban Dhaliwal¹, David Kendler², Kenneth Saag³, Steven Ing⁴, Andrea Singer⁵, Robert Adler⁶, Leny Pearman⁷, Yamei Wang⁷ and Bruce Mitlak⁸, ¹SUNY Upstate Medical University, Syracuse, NY, ²University of British Columbia, Vancouver, BC, Canada, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Ohio State University Wexner Medical Center, Colombus, OH, ⁵MedStar Georgetown University Hospital, Washington, DC, ⁶Hunter Holmes McGuire Veterans Affairs Medical Center-Richmond, Richmond, VA, ⁷Radius Health, Inc., Waltham, MA, ⁸Radius Health, Inc, Boston, MA
Background/Purpose: In the Abaloparatide for the Treatment of Men with Osteoporosis (ATOM) study, 12 months of abaloparatide therapy resulted in rapid and significant improvements in…
Abstract Number: 1322 • ACR Convergence 2022
Follow up of Incidentally Noted Vertebral Compression Fractures
Jason Yang¹, Alexia Hwang¹, Megan Brochu², Krista Sabina², Meridith Malysz², Bruce Weinstein³ and Jonathan Cheah¹, ¹UMass Chan Medical School, Worcester, MA, ²UMass Memorial Health, Worcester, MA, ³UMass Memorial Health, UMass Chan Medical School, Worcester, MA
Background/Purpose: Vertebral compression fractures (VCFs) in general represent a clinical diagnosis of osteoporosis, predisposing to an increased risk of additional fractures. However, a significant number…
Abstract Number: 1323 • ACR Convergence 2022
Secondary Prevention of Vertebral Fractures Sustained Efficacy over Time
JOSE ELOY OLLER RODRIGUEZ¹, Elena Grau García², Samuel Leal Rodriguez³, Laura Mas Sanchez², Pablo Francisco Muñoz Martínez⁴, Carmen Riesco Bárcena⁵, Anderson Huaylla Quispe⁶, Cristobal Pavez Perales², Francisco Miguel Ortiz Sanjuan⁷, José Ivorra Cortés², Inés Cánovas Olmos², Luis González Puig⁸, Isabel Martínez-Cordellat², Carmen Nájera Herranz⁷, Rosa Negueroles Albuixech², Elvira Vicens Bernabeu⁷, Alba Torrat Novés⁵, Daniel Ramos Castro² and José andrés Román ivorra³, ¹Hospital Universitario de La Fe, València, Spain, ²Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Spain, ³Hospital Universitari i Politécnic La Fe, València, Spain, ⁴Hospital Universitario y Politécnico La Fe, València, Spain, ⁵Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, ⁶Medicina, València, Spain, ⁷Hospital Universitario de La Fe, València, ⁸Rheumatology Department. Hospital Universitario y Politécnico La Fe, Torrente, Valencia, Spain
Background/Purpose: Vertebral fractures entail a notorious social and health problem, and their presence is the greatest risk factor for the appearance of a new vertebral…
Abstract Number: 1324 • ACR Convergence 2022
Treatment Patterns in Women with Post-Menopausal Osteoporosis Using Abaloparatide: A Real-world Observational Study
Deborah Gold¹, Tammy Beckett², Chad Deal³, Andrew L James⁴, Jacqueline M Kernaghan⁵, Mahshid Mohseni⁶, Abigail McMillan⁷, Tom Bailey⁷, Leny Pearman⁸, John Caminis⁸, Yamei Wang⁸ and Setareh A Williams⁹, ¹Duke University Medical Center, Durham, NC, ²Department of Orthopaedics, Orthopaedic Associates of Grand Rapids Research and Education Institute, Grand Rapids, MI, ³Cleveland Clinic, Shaker Heights, OH, ⁴Columbia Orthopaedic Groups LLP, Columbia, MO, ⁵Prospect Health Access Network, Springfield, PA, ⁶Washington University School of Medicine, St. Louis, MO, ⁷Observational Research Adelphi Real World, Macclesfield, United Kingdom, ⁸Radius Health, Inc., Waltham, MA, ⁹CobbsCreek Healthcare, Newtown Square, PA
Background/Purpose: Abaloparatide (ABL) is approved for treatment of women with postmenopausal osteoporosis (PMO) at high risk for fracture. The study evaluated real-world treatment patterns for…
Abstract Number: 0445 • ACR Convergence 2021
Safety and Efficacy of Denosumab vs Risedronate in Patients with Glucocorticoid-Induced Osteoporosis and Rheumatoid Arthritis
Jonathan Adachi¹, Arkadi Chines², Shuang Huang², Kenneth Saag³, Willem Lems⁴ and Piet Geusens⁵, ¹McMaster University/St. Joseph's Healthcare, Hamilton, ON, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴VUmc, Amsterdam, Netherlands, ⁵Maastricht University, Genk, Belgium
Background/Purpose: Denosumab (DMAb) is approved for the treatment of glucocorticoid (GC)–induced osteoporosis (GiOP). In a phase 3, international, active-controlled, double-blind, double-dummy study, treatment with DMAb…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].